Following this encouraging result, a further phase III clinical trial in KRAS-mutant lung cancer was conducted, which, however, failed to reproduce the significant benefit in patients treated with the combination compared with docetaxel alone (48). The gene discussed is KRAS; the disease is lung cancer.